News

The method could shed light on what goes awry in numerous brain conditions when neurons are correctly and incorrectly activated or inhibited.

Scripps Research scientists developed a compound that can block a protein previously considered challenging to drug and is implicated in autoimmune diseases, including lupus.

The ALSAM Foundation, founded by the Skaggs family, provides lasting gift to Scripps Research’s drug discovery and development arm.

By investigating a molecule in the brain tied to cellular communication, scientists uncover important information about the proteins that do—and do not—influence alcohol drinking behavior. 

For the last century, institute leaders and renowned scientists have made Scripps Research what it is today: the world’s leading independent and nonprofit biomedical research institute at the forefront of innovation.

Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical care.  A Phase 1 trial has been initiated to evaluate GS-1614 - a novel prodrug of a nucleoside reverse transcriptase translocation inhibitor (NRTTI).

Lay, founder of the global biotech company BioLegend, brings invaluable experience as an industry leader and innovator. 

Scripps Research scientists develop a new, high-resolution technique for finding potential therapeutic targets on proteins in living cells. The findings could lead to more targeted therapeutics for nearly any human disease.

Following approval from Australia’s HREC, the clinical trial investigating UVAX-1107 and UXAX-1197 will initiate in January 2024.  

Scripps Research team modifies the traditional poison picrotoxinin for potential neurological drugs and anti-parasite treatments.

Topol provides an overview of how AI models can improve diagnostic accuracy, liberate clinicians from keyboards and restore the doctor-patient relationship.

Scripps Research scientists and collaborators uncovered the relative effectiveness of different COVID-19 mandates, helping guide public health policy for future viral threats.

Early detection of atrial fibrillation can reduce the risk of stroke and heart failure, but screening people for the condition has been historically challenging.

Scripps Research-designed vaccine could provide broad, enduring protection against influenza A strains, including pandemic strains

Clarivate’s annual, global list represents researchers who have demonstrated significant and broad influence in their field of research.

Immunology assistant professor Joseph Jardine and assistant neuroscience professor Chen Ran join the faculty, while RNA-targeting expert Megan Ken becomes the newest fellow

The Ben Barres Early Career Acceleration Award recognizes Ye’s pioneering research into how the communication between our brain and body impacts neurodegenerative diseases.

Late-breaking data reinforces the effectiveness and safety of ozanimod, invented in the labs of professors Hugh Rosen and Edward Roberts.

Combining precise genome engineering and protein activity profiling to methodically study thousands of cancer genes, Scripps Research scientists were able to pinpoint promising cancer drug targets.

The prestigious award will support Lasker’s inventive research in membraneless organelles and their application in neurodegenerative diseases.

The prestigious award will support Bollong’s research identifying new molecular targets and therapeutics, including in regenerative organ repair.

Dawson is honored with the Arthur C. Cope Late Careers Scholar Award for his foundational contributions in organic chemistry.

The method represents a new toolkit for making drugs and other compounds.

New findings suggest that treating insomnia can stop opioid-seeking behavior, even after ending treatment.